Zentalis Pharmaceuticals, Inc. Common Stock (ZNTL) Stock Price

ZNTLStock
$3.88+88.94%52W
Market Cap$367.33M
P/E
PEG Ratio
Div yield
Beta1.95

ZNTL Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)45.42%
Price vs S&P 500 (4W)-21.67%
VGM Score71.35

ZNTL Earnings Surprise History

Q2 25-0.37est. -0.52
Q3 25-0.37est. -0.48
Q4 25-0.49est. -0.61
Q2 26-0.59est. -0.48

ZNTL Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
3.87
3.87
3.87
3.88

Industry Peers — Pharmaceuticals(571)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
ZNTLZentalis Pharmaceuticals, Inc. Common Stock
B$3.88
LLYEli Lilly & Co.DBB$1233.66
JNJJohnson & JohnsonDCB$273.14
ABBVABBVIE INC.DCB$265.79
MRKMerck & Co., Inc.DCA$156.45
NVSNovartis AGCCC$159.98
AZNAstraZeneca PLCCBC$169.66
NVONovo-Nordisk A/SBCC$48.66
ABTAbbott LaboratoriesCCB$116.13
PFEPfizer Inc.CDC$28.57
VRTXVertex Pharmaceuticals IncDCB$552.85

About Zentalis Pharmaceuticals, Inc. Common Stock

Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company developing azenosertib, a potentially first-in-class WEE1 inhibitor for Cyclin E1-positive platinum-resistant ovarian cancer. The company's lead program targets a specific patient population with limited existing treatment options and represents a focused therapeutic approach to an underserved indication.